Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


Gov 'obfuscation' costing lives

Posted 10 June 2021 AM

As gene therapies that offer potentially curative outcomes for childhood disease emerge, the federal government has been slammed for constructing a process around newborn screening that is so complex it puts Australia almost 150 years behind the US.

According to Better Access Australia (BAA) the current system to determine which conditions should be included in newborn screening should be scrapped and replaced with a single review with a six month time limit.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Could access probe be for nothing?
Significant industry participation but what outcome?
Approvals Action
Injectable antibiotic ticked
Fresenius Kabi adds to Gram-positive options